Long-term efficacy of antipsychotic drugs in initially acutely ill adults with schizophrenia: systematic review and network meta-analysis.
Antipsychotics
all-cause discontinuation
long-term efficacy
negative symptoms
olanzapine
positive symptoms
schizophrenia
weight gain
Journal
World psychiatry : official journal of the World Psychiatric Association (WPA)
ISSN: 1723-8617
Titre abrégé: World Psychiatry
Pays: Italy
ID NLM: 101189643
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
accepted:
09
02
2023
medline:
9
5
2023
pubmed:
9
5
2023
entrez:
9
5
2023
Statut:
ppublish
Résumé
Most acute phase antipsychotic drug trials in schizophrenia last only a few weeks, but patients must usually take these drugs much longer. We examined the long-term efficacy of antipsychotic drugs in acutely ill patients using network meta-analysis. We searched the Cochrane Schizophrenia Group register up to March 6, 2022 for randomized, blinded trials of at least 6-month duration on all second-generation and 18 first-generation antipsychotics. The primary outcome was change in overall symptoms of schizophrenia; secondary outcomes were all-cause discontinuation; change in positive, negative and depressive symptoms; quality of life, social functioning, weight gain, antiparkinson medication use, akathisia, serum prolactin level, QTc prolongation, and sedation. Confidence in the results was assessed by the CINeMA (Confidence in Network Meta-Analysis) framework. We included 45 studies with 11,238 participants. In terms of overall symptoms, olanzapine was on average more efficacious than ziprasidone (standardized mean difference, SMD=0.37, 95% CI: 0.26-0.49), asenapine (SMD=0.33, 95% CI: 0.21-0.45), iloperidone (SMD=0.32, 95% CI: 0.15-0.49), paliperidone (SMD=0.28, 95% CI: 0.11-0.44), haloperidol (SMD=0.27, 95% CI: 0.14-0.39), quetiapine (SMD=0.25, 95% CI: 0.12-0.38), aripiprazole (SMD=0.16, 95% CI: 0.04-0.28) and risperidone (SMD=0.12, 95% CI: 0.03-0.21). The 95% CIs for olanzapine versus aripiprazole and risperidone included the possibility of trivial effects. The differences between olanzapine and lurasidone, amisulpride, perphenazine, clozapine and zotepine were either small or uncertain. These results were robust in sensitivity analyses and in line with other efficacy outcomes and all-cause discontinuation. Concerning weight gain, the impact of olanzapine was higher than all other antipsychotics, with a mean difference ranging from -4.58 kg (95% CI: -5.33 to -3.83) compared to ziprasidone to -2.30 kg (95% CI: -3.35 to -1.25) compared to amisulpride. Our data suggest that olanzapine is more efficacious than a number of other antipsychotic drugs in the longer term, but its efficacy must be weighed against its side effect profile.
Identifiants
pubmed: 37159349
doi: 10.1002/wps.21089
pmc: PMC10168166
doi:
Types de publication
Journal Article
Langues
eng
Pagination
315-324Informations de copyright
© 2023 World Psychiatric Association.
Références
Eur Arch Psychiatry Clin Neurosci. 2022 Feb;272(1):1-3
pubmed: 35038002
J Clin Psychopharmacol. 2006 Apr;26(2):157-62
pubmed: 16633144
World Psychiatry. 2023 Feb;22(1):116-128
pubmed: 36640396
Prog Neuropsychopharmacol Biol Psychiatry. 2004 Mar;28(2):311-8
pubmed: 14751428
Schizophr Res. 2013 Jun;147(1):95-102
pubmed: 23583011
Syst Rev. 2022 Sep 9;11(1):198
pubmed: 36085250
Ann Intern Med. 2013 Jul 16;159(2):130-7
pubmed: 23856683
PLoS Med. 2020 Apr 3;17(4):e1003082
pubmed: 32243458
Indian J Psychol Med. 2011 Jul;33(2):134-40
pubmed: 22345836
N Engl J Med. 2005 Sep 22;353(12):1209-23
pubmed: 16172203
Am J Psychiatry. 2010 Jun;167(6):686-93
pubmed: 20360319
World Psychiatry. 2022 Jun;21(2):295-307
pubmed: 35524620
Br J Psychiatry. 1999 Jan;174:15-22
pubmed: 10211146
Cochrane Database Syst Rev. 2022 Oct 3;10:CD013337
pubmed: 36190739
Int J Epidemiol. 2012 Jun;41(3):818-27
pubmed: 22461129
Lancet. 2012 Dec 15;380(9859):2163-96
pubmed: 23245607
Schizophr Bull. 1987;13(2):261-76
pubmed: 3616518
BMJ. 1998 Oct 31;317(7167):1181-4
pubmed: 9794850
J Clin Psychiatry. 2008 Apr;69(4):514-9
pubmed: 18370570
Lancet Psychiatry. 2022 Nov;9(11):884-893
pubmed: 36228647
J Clin Psychopharmacol. 2012 Feb;32(1):36-45
pubmed: 22198451
Res Synth Methods. 2016 Dec;7(4):346-370
pubmed: 26679486
J Clin Epidemiol. 2004 Nov;57(11):1124-30
pubmed: 15612138
Eur Psychiatry. 2010 Jun;25 Suppl 2:S12-21
pubmed: 20620881
J Clin Psychopharmacol. 2006 Oct;26(5):453-61
pubmed: 16974184
JAMA. 2003 Nov 26;290(20):2693-702
pubmed: 14645311
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
Res Synth Methods. 2012 Jun;3(2):98-110
pubmed: 26062084
Stat Med. 2010 Mar 30;29(7-8):932-44
pubmed: 20213715
Lancet. 2019 Sep 14;394(10202):939-951
pubmed: 31303314
Lancet. 2022 Feb 26;399(10327):824-836
pubmed: 35219395